Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ergoloid mesylate
- Development stage
- Unknown
- Lead developer
- Sandoz
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Administration
- Oral, Sublingual, Intramuscular, Intravenous
01
Overview
Ergoloid mesylate is a mixture of three hydrogenated ergot alkaloids—dihydroergocornine, dihydroergocristine, and dihydroergocryptine—derived from the fungus *Claviceps purpurea*. It is classified as an ergot derivative and used primarily to treat symptoms of cognitive decline or dementia in elderly patients, including those associated with Alzheimer's disease or multiple small strokes. The drug acts as a nootropic (cognitive enhancer), though its precise mechanism of action remains unclear. It is believed to exert partial agonist/antagonist effects on adrenergic (alpha and beta), dopaminergic, and serotonergic receptors in the brain. Ergoloid mesylate may increase cerebral blood flow and metabolism but does not cure dementia or underlying neurodegenerative diseases[1][3][4][5][7][8]. Developers: Sandoz Manufacturers: Novartis
- Brand names
- HydergineHydergine LC
- Other names
- ergoloid mesylatesdihydroergotoxinedihydrogenated ergot alkaloids
02
Targets
DRD1 (Dopamine D1 Receptor)ADRB1 (β1)DRD2 (Dopamine D2 Receptor)GABRR (GABA-A receptor subunit rho)ADRA1A (α1A)DRD3 (Dopamine receptor D3)
Beyond the preview
Go deeper on ergoloid mesylate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ergoloid mesylate.